Boston Partners’s Novo Nordisk NVO Stock Holding History

Boston Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.3M	Buy	507,489 +362,469	+250%	+$15.6M	0.02%	369
2026 Q1	$5.33M	Sell	145,020 -5,231,804	-97%	-$248M	0.01%	480
2025 Q4	$276M	Sell	5,376,824 -194,193	-3%	-$9.93M	0.29%	122
2025 Q3	$310M	Buy	+5,571,017	New	+$326M	0.32%	108
2020 Q2	–	Sell	-2,499,362	Closed	-$75.2M	–	686
2020 Q1	$75.2M	Sell	2,499,362 -1,674,248	-40%	-$49.9M	0.15%	171
2019 Q4	$121M	Sell	4,173,610 -176,992	-4%	-$4.9M	0.16%	172
2019 Q3	$113M	Sell	4,350,602 -117,540	-3%	-$2.97M	0.15%	173
2019 Q2	$114M	Sell	4,468,142 -47,278	-1%	-$1.17M	0.15%	175
2019 Q1	$118M	Buy	4,515,420 +175,756	+4%	+$4.32M	0.16%	166
2018 Q4	$100M	Buy	+4,339,664	New	+$96.4M	0.14%	176

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Boston Partners's NVO Position: Q2 2026 in Review

Boston Partners increased its Novo Nordisk (NVO) stake by 250% in Q2 2026, buying an estimated $15.6M and bringing the position to 507,489 shares worth $24.3M. The position accounts for 0.02% of the portfolio, ranked #369.

Boston Partners first reported a position in NVO in Q4 2018 and has held it in 10 quarters since. The position peaked at $310M in Q3 2025. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Boston Partners held 507,489 shares of Novo Nordisk worth $24.3M as of Q2 2026.
Boston Partners bought 362,469 Novo Nordisk shares in Q2 2026, an estimated $15.6M.
Novo Nordisk made up 0.02% of Boston Partners's portfolio in Q2 2026, its #369 holding.
Boston Partners first reported a position in Novo Nordisk in Q4 2018 and has held it in 10 quarters since.
Boston Partners's Novo Nordisk position peaked at $310M in Q3 2025.
1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Boston Partners's 13F filing for Q2 2026, filed 4 Aug 2026.